Safe by Design: Unbiased Tools for CRISPR Safety in Cell and Gene Therapy

28 Jan 2026
Advanced Therapies Stage
  • Unbiased, PCR-free strategies for genome-wide CRISPR safety assessment 
  • Chromosomal stability as a key metric for off- and on-target evaluation 
  • Optical genome mapping versus conventional PCR approaches 
  • Novel image-based methods for Cas9 off-target detection 
  • Implications for designing safer cell and gene therapies 
Speakers
Roberto Nitsch
Roberto Nitsch, Director, Gene Therapy Safety -  AstraZeneca